TScan Therapeutics financials
$0.3175−6.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M |
| Gross profit | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$135.8M | -$134.8M | -$93.5M | -$66.6M | -$48.6M |
| Net income | -$129.8M | -$127.5M | -$89.2M | -$66.2M | -$48.6M |
| Net margin | −1256.8% | −4527.7% | −423.9% | −489.3% | −479.5% |
| Diluted EPS | $-1.00 | $-1.14 | $-1.36 | $-2.75 | $-4.17 |
| EBITDA | -$132.9M | -$130.7M | -$88.1M | -$61.5M | -$45.3M |
| Operating cash flow | -$135.3M | -$110.8M | -$61.4M | -$66.5M | -$48.7M |
| Free cash flow | -$139.7M | -$114.6M | -$64.5M | -$70.7M | -$58.6M |
| Diluted shares | 129.8M | 112.0M | 65.6M | 24.0M | 11.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $152.4M | $178.7M | $133.4M | $120.0M | $161.4M |
| Short-term investments | $0.00 | $111.4M | $58.7M | $0.00 | — |
| Total debt | $32.5M | $32.1M | $30.0M | $29.3M | $0.00 |
| Total assets | $228.8M | $371.1M | $272.1M | $199.1M | $188.1M |
| Total liabilities | $105.7M | $130.1M | $121.3M | $99.7M | $27.3M |
| Shareholders' equity | $123.1M | $241.0M | $150.9M | $99.4M | $160.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology